Vertex’s CF Therapy Combination Trial Yields Promising Lung-Function Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Interim data from a Phase II study investigating Kalydeco with VX-809 showed statistically significant FEV-1 improvement across dosing groups; the company hopes to start a pivotal Phase III program for the combo in late 2012 or early 2013.